Phase 3Active, not recruiting
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (CAPItana)
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
- Sponsor
- AstraZeneca (Industry)
- Enrolment
- 101 enrolled
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Fulvestrant; Capivasertib
- Ages
- adults, older adults
- Registry
- NCT06764186
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with PIK3CA/AKT1/PTEN-altered following recurrence or progression on or after endocrine therapy and CDK4/6 inhibitor.
Primary outcomes
- Time to next treatment (TTNT)
History
Primary completion expected
Last registry update
Registered
Started